Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Company Deals

Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal

Fineline Cube Dec 17, 2025
Company Deals

Hansoh Licenses EGFR Drug Aumolertinib to Glenmark for $1B+ in Milestones

Fineline Cube Dec 17, 2025
Company Deals

Fangzhou and Huilun Partner on AI-Driven Chronic Disease Management Platform

Fineline Cube Dec 17, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Fineline Cube Dec 18, 2025
Company Drug

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

Fineline Cube Dec 18, 2025
Company

Everest Medicines Appoints Rogers Yongqing Luo as New CEO

Fineline Cube Sep 19, 2022

China-based biotech Everest Medicines (HKG: 1952) has announced the appointment of a new CEO, Rogers...

Drug Policy / Regulatory

Hainan’s Lecheng Zone Updates Special Drug Insurance List with Expanded Coverage

Fineline Cube Sep 16, 2022

Hainan Boao Lecheng International Medical Tourism Pilot Zone has released an updated special drug insurance...

Company Deals

Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development

Fineline Cube Sep 16, 2022

China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly...

Company Digital

Best Covered Raises RMB 100 Million in Series A+ Funding for Cognitive Impairment Solution

Fineline Cube Sep 16, 2022

Shanghai-based digital cognitive impairment solution provider Best Covered reportedly raised RMB 100 million (USD 14.2...

Company Deals Policy / Regulatory

US Blocks Asymchem’s Acquisition of Snapdragon Chemistry

Fineline Cube Sep 16, 2022

US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization...

Company Drug

Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22

Fineline Cube Sep 16, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...

Policy / Regulatory

CDE Issues Guidelines for Anti-Tumor ADC Clinical Development

Fineline Cube Sep 16, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company

Eli Lilly Announces Global C-Suite Changes, New Leadership in China

Fineline Cube Sep 16, 2022

US-based pharmaceutical giant Eli Lilly (NYSE: LLY) announced significant changes to its global C-suite. Julio...

Company Policy / Regulatory

China’s Policy Shifts Medical Device Procurement Toward Domestic Products

Fineline Cube Sep 16, 2022

Local government policies in China have begun to direct public hospitals to prioritize the procurement...

Company

Antengene Expands to Australia with New Melbourne Office

Fineline Cube Sep 16, 2022

China-based biotech firm Antengene (HKG: 6996) announced the opening of its new office in Melbourne,...

Company Deals

Great Bay Bio Completes USD 15M Pre-Series B Financing to Advance AI Bioprocessing Platforms

Fineline Cube Sep 15, 2022

Great Bay Bio (GBB), a Hong Kong-based biotechnology firm, announced the completion of a USD...

Company Deals

Zhonghong Pulin Partners with Shanghai Pharma for Logistics and Distribution

Fineline Cube Sep 15, 2022

China-based Zhonghong Pulin Medical Product Co., Ltd (SHE: 300981) has entered into a partnership with...

Company Deals

Suzhou Jade Biomedical Secures USD 10 Million Series B Financing

Fineline Cube Sep 15, 2022

China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B...

Company Deals

Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding

Fineline Cube Sep 15, 2022

Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD...

Company Deals

Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center

Fineline Cube Sep 15, 2022

China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and...

Company Deals

Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion

Fineline Cube Sep 15, 2022

Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196),...

Company Drug

Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance

Fineline Cube Sep 15, 2022

China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized...

Company Deals

Bide Pharmatech Set for IPO on Shanghai’s STAR Market

Fineline Cube Sep 15, 2022

Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...

Drug Policy / Regulatory

NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Sep 15, 2022

The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for...

Company Drug

Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment

Fineline Cube Sep 15, 2022

Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the...

Posts pagination

1 … 557 558 559 … 599

Recent updates

  • Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication
  • Everest lerodalcibep PCSK9 FDA Approval Targets China Launch
  • Cryofocus GERD System Secures NMPA Approval in China
  • Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody
  • Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Antengene Xpovio sNDA Malaysia Approval Expands DLBCL Indication

Company Drug

Everest lerodalcibep PCSK9 FDA Approval Targets China Launch

Company Medical Device

Cryofocus GERD System Secures NMPA Approval in China

Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.